These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27751785)

  • 1. Circulating biomarkers to guide systemic therapy for urothelial carcinoma.
    Abbosh PH; Rosenberg JE; Plimack ER
    Urol Oncol; 2016 Nov; 34(11):502-509. PubMed ID: 27751785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.
    Rink M; Schwarzenbach H; Riethdorf S; Soave A
    World J Urol; 2019 Sep; 37(9):1785-1799. PubMed ID: 30367205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?
    Miyamoto DT; Lee RJ
    Urol Oncol; 2016 Nov; 34(11):490-501. PubMed ID: 27771279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
    Zhang T; Zhu J; George DJ; Nixon AB
    Urol Oncol; 2016 Nov; 34(11):510-518. PubMed ID: 27498927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
    Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of circulating tumor cells in bladder cancer patients.
    Nezos A; Pissimisis N; Lembessis P; Sourla A; Dimopoulos P; Dimopoulos T; Tzelepis K; Koutsilieris M
    Cancer Treat Rev; 2009 May; 35(3):272-9. PubMed ID: 19103472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma.
    Powles T; Morrison L
    Nat Rev Urol; 2018 Oct; 15(10):585-587. PubMed ID: 30030491
    [No Abstract]   [Full Text] [Related]  

  • 9. Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction.
    Yang Y; Miller CR; Lopez-Beltran A; Montironi R; Cheng M; Zhang S; Koch MO; Kaimakliotis HZ; Cheng L
    Crit Rev Oncog; 2017; 22(5-6):389-401. PubMed ID: 29604919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
    Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K
    PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer.
    Lu JJ; Kakehi Y; Takahashi T; Wu XX; Yuasa T; Yoshiki T; Okada Y; Terachi T; Ogawa O
    Clin Cancer Res; 2000 Aug; 6(8):3166-71. PubMed ID: 10955799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating urothelial cancer cells in the blood using the CellSearch System.
    Naoe M; Ogawa Y; Morita J; Omori K; Takeshita K; Shichijyo T; Okumura T; Igarashi A; Yanaihara A; Iwamoto S; Fukagai T; Miyazaki A; Yoshida H
    Cancer; 2007 Apr; 109(7):1439-45. PubMed ID: 17326057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM; Luo B; Ye NY; Xie K; Ye SR
    Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
    Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
    Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel agents for muscle-invasive and advanced urothelial cancer.
    Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
    BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer.
    Gazzaniga P; de Berardinis E; Raimondi C; Gradilone A; Busetto GM; De Falco E; Nicolazzo C; Giovannone R; Gentile V; Cortesi E; Pantel K
    Int J Cancer; 2014 Oct; 135(8):1978-82. PubMed ID: 24599551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma.
    Yaegashi H; Izumi K; Kadomoto S; Naito R; Makino T; Iwamoto H; Nohara T; Shigehara K; Kadono Y; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):375-380. PubMed ID: 30591483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Biomarkers for Prediction of Treatment Response.
    Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.